Single agent zimberelimab clinical trials

Zimberelimab Anti-PD1 +/- Domvanalimab in Resectable Mmrd Gastric Cancer

This study is testing new drug combinations for stomach and gullet cancer that have a specific genetic marker. It aims to see if these drugs can shrink tumours before surgery, potentially reducing the need for strong chemotherapy.